After 6 weeks of deafness with neurotrophic treatment, survival of both SGCs and their PPs was generally substantially higher (Figures 2E–G; BDNF, NT-3, and Cocktail, respectively) than the PBS control group. The gene discussed is NTF3; the disease is deafness.